G&L Scientific Inc announces the opening of new offices in Basel, Switzerland

Basel, October 2nd, 2019 G&L Scientific Inc., a market-leading, multinational, scientific consultancy with over 25 years at the forefront of Regulatory Affairs and Quality Assurance, has announced the opening of new offices in Basel, Switzerland.

The company cites increased demand from clients in Continental Europe as the driver for this latest expansion.

“The opening of these additional offices in Switzerland reaffirms G&L’s commitment to both new and existing clients in Europe — an area of key strategic focus for us. It will enable us to provide new and emerging companies with the strengths of a global Regulatory Affairs and Quality Assurance consultancy, combined with local market expertise,” said CEO, Stephen Loughrey.

Mr. Loughrey added: “We look forward to this expansion and the opportunity to better serve our clients in Europe as we grow and strengthen our presence in this important market.”

About G&L Scientific:
G&L is a market-leading, multi-national, scientific consultancy with over 25 years at the cutting-edge of Regulatory Affairs and Quality Assurance.

The industry sectors served by G&L include Pharmaceuticals, Biologics, Medical Devices, Consumer Health, Animal Health and Generics.

G&L’s engagement models include: Functional Service Provision, Portfolio Outsourcing, Strategic Consulting and Contingent Resource Provision.

The company has a significant International presence, with multiple offices around the globe, and a large international consultant base. It has proven expertise in providing solutions for all ranges of scientific assignments, regardless of size, location or timescale.
G&L focuses solely on Regulatory Affairs and Quality Assurance.

For more information on G&L Scientific’s new office, please call +41 (0) 61 564 07 26 or email hello.europe@gandlscientific.com

Company Locations:
United States
Canada
United Kingdom
India
Switzerland

Source: RealWire

user

Recent Posts

Hemogenyx Pharmaceuticals PLC Announces IRB Approval for Phase I Clinical Trial

Hemogenyx Pharmaceuticals Receives IRB Approval for Phase 1 Clinical Trial of HEMO-CAR-T (HG-CT-1)LONDON, UK /…

5 hours ago

Modular Medical Announces Pricing of $8.2 Million Public Offering

SAN DIEGO, CA / ACCESSWIRE / November 21, 2024 / Modular Medical, Inc. (Nasdaq:MODD) ("Modular…

8 hours ago

Nicole Garrett and Under Pressure Hyperbarics Lead the Charge in Wellness Education With Immersive Events at L.A. Fashion Weekend and Beyond

BEVERLY HILLS, CALIFORNIA / ACCESSWIRE / November 21, 2024 / Nicole Garrett, CEO of Under…

11 hours ago

Beacon Healthcare Systems Expands Leadership Team with Addition of Ayman Mohamed as Chief Technology Officer

HUNTINGTON BEACH, Calif., Nov. 21, 2024 /PRNewswire/ -- Beacon Healthcare Systems, is pleased to announce…

14 hours ago

Talkiatry Ranked Number 6 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™

Attributes Revenue Growth to Innovative Partnerships, Strong Team, and Unique Value-Based Care Model NEW YORK,…

14 hours ago

Bright Light Imaging Leverages Alpha Nodus’s Gravity Auth, Enhanced by Integration with ADS’s MedicsRIS, to Streamline Patient Care

Automation That Makes a Difference SUNRISE, Fla., Nov. 21, 2024 /PRNewswire/ -- When it comes…

14 hours ago